A citation-based method for searching scientific literature

Curtis D Chin, Charlene M Fares, Gottfried E Konecny, Jianyu Rao. Curr Opin Obstet Gynecol 2020
Times Cited: 3







List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Treatment of recurrent ovarian cancer.
S Pignata, S C Cecere, A Du Bois, P Harter, F Heitz. Ann Oncol 2017
77
66

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan. Nat Rev Cancer 2019
734
66

Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Gregory M Chen, Lavanya Kannan, Ludwig Geistlinger, Victor Kofia, Zhaleh Safikhani, Deena M A Gendoo, Giovanni Parmigiani, Michael Birrer, Benjamin Haibe-Kains, Levi Waldron. Clin Cancer Res 2018
37
66

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
989
66

Ovarian Cancer Immunotherapy: Turning up the Heat.
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega. Int J Mol Sci 2019
57
66


The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Galaxia M Rodriguez, Kristianne J C Galpin, Curtis W McCloskey, Barbara C Vanderhyden. Cancers (Basel) 2018
52
66

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Marco Greppi, Giovanna Tabellini, Ornella Patrizi, Simona Candiani, Andrea Decensi, Silvia Parolini, Simona Sivori, Silvia Pesce, Laura Paleari, Emanuela Marcenaro. Int J Mol Sci 2019
17
66



Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
66

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.
Curtis W McCloskey, Galaxia M Rodriguez, Kristianne J C Galpin, Barbara C Vanderhyden. Cancers (Basel) 2018
20
66

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Emina Torlakovic, Hyun J Lim, Julien Adam, Penny Barnes, Gilbert Bigras, Anthony W H Chan, Carol C Cheung, Jin-Haeng Chung, Christian Couture, Pierre O Fiset,[...]. Mod Pathol 2020
62
33

Beyond chemotherapy: targeted therapies in ovarian cancer.
Timothy A Yap, Craig P Carden, Stan B Kaye. Nat Rev Cancer 2009
368
33

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
998
33

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon C Rebelatto, Jill Walker. Diagn Pathol 2019
17
33

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
David L Rimm, Gang Han, Janis M Taube, Eunhee S Yi, Julia A Bridge, Douglas B Flieder, Robert Homer, William W West, Hong Wu, Anja C Roden,[...]. JAMA Oncol 2017
451
33

Diagnosis of multiple cancer types by shrunken centroids of gene expression.
Robert Tibshirani, Trevor Hastie, Balasubramanian Narasimhan, Gilbert Chu. Proc Natl Acad Sci U S A 2002
33

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
81
33

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Margarita Udall, Maria Rizzo, Juliet Kenny, Jim Doherty, SueAnn Dahm, Paul Robbins, Eric Faulkner. Diagn Pathol 2018
97
33

"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Alison Davis, Anna V Tinker, Michael Friedlander. Gynecol Oncol 2014
169
33

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Klaus Pietzner, Sara Nasser, Sara Alavi, Silvia Darb-Esfahani, Mona Passler, Mustafa Zelal Muallem, Jalid Sehouli. J Gynecol Oncol 2018
18
33

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
33

Metagenes and molecular pattern discovery using matrix factorization.
Jean-Philippe Brunet, Pablo Tamayo, Todd R Golub, Jill P Mesirov. Proc Natl Acad Sci U S A 2004
687
33

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, Gabriela Turcu, Marina K Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L Rimm, Yuval Kluger, Lieping Chen,[...]. Clin Cancer Res 2017
78
33

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
33

High response rate to PD-1 blockade in desmoplastic melanomas.
Zeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, Dae Won Kim, Alain Algazi, Douglas B Johnson, Elizabeth Liniker, Ben Kong, Rodrigo Munhoz, Suthee Rapisuwon,[...]. Nature 2018
138
33

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
655
33

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
33

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
33

Significance analysis of microarrays applied to the ionizing radiation response.
V G Tusher, R Tibshirani, G Chu. Proc Natl Acad Sci U S A 2001
33

Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Evan J Lipson, Patrick M Forde, Hans-Joerg Hammers, Leisha A Emens, Janis M Taube, Suzanne L Topalian. Semin Oncol 2015
173
33

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
33

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
747
33

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.
Tara Castellano, Kathleen N Moore, Laura L Holman. Clin Ther 2018
11
33

PD-1/PD-L1 inhibitors.
Joel Sunshine, Janis M Taube. Curr Opin Pharmacol 2015
294
33

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.
Veronica Rojas, Kim M Hirshfield, Shridar Ganesan, Lorna Rodriguez-Rodriguez. Int J Mol Sci 2016
83
33


PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Mark Yarchoan, Lee A Albacker, Alexander C Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena T Vithayathil, Neeha Zaidi, Nilofer S Azad, Daniel A Laheru, Garrett M Frampton,[...]. JCI Insight 2019
134
33

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Gottfried E Konecny, Chen Wang, Habib Hamidi, Boris Winterhoff, Kimberly R Kalli, Judy Dering, Charles Ginther, Hsiao-Wang Chen, Sean Dowdy, William Cliby,[...]. J Natl Cancer Inst 2014
197
33

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Bharathi Vennapusa, Brian Baker, Marcin Kowanetz, Jennifer Boone, Ina Menzl, Jean-Marie Bruey, Gregg Fine, Sanjeev Mariathasan, Ian McCaffery, Simonetta Mocci,[...]. Appl Immunohistochem Mol Morphol 2019
79
33


Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M Fares, Eliezer M Van Allen, Charles G Drake, James P Allison, Siwen Hu-Lieskovan. Am Soc Clin Oncol Educ Book 2019
179
33

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010
342
33

Molecular subtyping of cancer: current status and moving toward clinical applications.
Lan Zhao, Victor H F Lee, Michael K Ng, Hong Yan, Maarten F Bijlsma. Brief Bioinform 2019
24
33

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M Marincola, Alessandra Cesano. J Immunother Cancer 2018
125
33


A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, Laura J van't Veer, Hongyue Dai, Augustinus A M Hart, Dorien W Voskuil, George J Schreiber, Johannes L Peterse, Chris Roberts, Matthew J Marton,[...]. N Engl J Med 2002
33


BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
Verena Wieser, Inge Gaugg, Martina Fleischer, Giridhar Shivalingaiah, Soeren Wenzel, Susanne Sprung, Sigurd F Lax, Alain G Zeimet, Heidelinde Fiegl, Christian Marth. Oncotarget 2018
46
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.